MAIA

MAIA Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

MAIA Biotechnology, Inc. (MAIA), a Delaware corporation, filed this Current Report on Form 8-K on January 20, 2026. The Company is an emerging growth company with its principal executive offices in Chicago, IL. The filing reports on events occurring on January 20, 2026, specifically the issuance of a press release regarding the advancement of its Ateganosine cancer treatment program and the outlining of 2026 clinical milestones.

Key Financial Metrics

This filing does not contain specific financial data. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. As a clinical-stage biotechnology company, the filing focuses on operational milestones rather than financial performance metrics.

Material Changes

The material event reported is the advancement of the Ateganosine cancer treatment program. The Company outlined specific clinical milestones and growth momentum for the year 2026. No quantitative financial changes versus prior periods are disclosed in this text.

Guidance, Outlook, and Risks

Outlook: Management has outlined 2026 clinical milestones and indicated growth momentum for the Ateganosine program. Risks and Contingencies: The filing includes extensive forward-looking statements subject to significant risks and uncertainties. Key risks include:

• Initiation, timing, cost, progress, and results of preclinical and clinical studies.
• Ability to advance product candidates into and successfully complete clinical studies.
• Timing or likelihood of regulatory filings and approvals.
• Ability to develop, manufacture, and commercialize product candidates.
• Market acceptance and growth potential of product candidates.
• Ability to obtain and maintain intellectual property protection.

The Company explicitly states it undertakes no obligation to update forward-looking statements except as required by law.

Investor Verification Checklist

• Verify the specific details of the 2026 clinical milestones for Ateganosine in the attached press release (Exhibit 99.1).
• Review the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K does not provide liquidity data.
• Monitor upcoming regulatory filings for updates on the Ateganosine clinical trial status.
• Assess the impact of the outlined milestones on the Company's capital requirements and potential dilution.